AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25245327 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interleukin-2 (HD-IL-2) at a dose of 18 MIU/m2/day by continuous IV infusion for 72 hours, repeated every 3 weeks for up to 4 cycles and then every 4 weeks for a further 2 cycles.
Number of subjects: 0
Study 25245327 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster radiotherapy (XRT) at 6-12 Gy administered in three daily doses on days -3 to -1 before the first and third cycle of IL-2.
Number of subjects: 0
Study 25245327 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HD-IL-2 and XRT.
Number of subjects: 0
Study 25245624 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 160 mg at the start, 80 mg 2 weeks later, followed by 40 mg every other week for 52 weeks (with some patients increasing to 80 mg every other week)
Number of subjects: 20
Study 25245624 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 20
Study 25245629 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab monotherapy
Number of subjects: 203
Study 25245629 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with azathioprine
Number of subjects: 203
Study 25245629 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with increased baseline levels of CRP
Number of subjects: 203
Study 25245629 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients evaluable for mucosal healing (MH)
Number of subjects: 203
Study 25246084 — intervention group
Group type: EXPERIMENTAL
Intervention: Early survivors with cardiogenic shock (CS)
Number of subjects: 3670
Study 25246084 — intervention group
Group type: COMPARATOR
Intervention: Patients without cardiogenic shock (CS)
Number of subjects: 3670
Study 25247300 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriage isolates of Neisseria meningitidis
Number of subjects: 268
Study 25247300 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccines targeting fHbp
Number of subjects: 268
Study 25248302 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMS adherence monitoring
Number of subjects: 201
Study 25248302 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 201
Study 25248302 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of adherence
Number of subjects: 201
Study 25248302 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence predictors
Number of subjects: 201
Study 25248302 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological predictors
Number of subjects: 201
Study 25248945 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate (ARS) 100, 150, or 200 mg OD
Number of subjects: 23
Study 25248945 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate (ARS)
Number of subjects: 23
Study 25249005 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week Contemplative Self-Healing Program (guided meditation and cognitive-affective-behavioral learning)
Number of subjects: 0
Study 25249760 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior graft location in the tibia
Number of subjects: 75
Study 25250055 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint application (AP)
Number of subjects: 200
Study 25250715 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed and cisplatin for 4 cycles, followed by pemetrexed maintenance for non-progressing patients
Number of subjects: 51
Study 25250858 — intervention group
Group type: EXPERIMENTAL
Intervention: RO4929097 (20 mg daily, 3 consecutive days per week)
Number of subjects: 36
Study 25251317 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h lower sleep duration after 200 days
Number of subjects: 441
Study 25251317 — intervention group
Group type: COMPARATOR
Intervention: Baseline sleep duration
Number of subjects: 441
Study 25253045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral panobinostat (30 mg single dose for core phase, then thrice-weekly for extension phase)
Number of subjects: 25
Study 25253674 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cell mass cytometry analysis of immune responses
Number of subjects: 32
Study 25253770 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (AZD6244, ARRY-142886)
Number of subjects: 206
Study 25253770 — intervention group
Group type: COMPARATOR
Intervention: Ras pathway mutations
Number of subjects: 206
Study 25253770 — intervention group
Group type: COMPARATOR
Intervention: KRAS mutations
Number of subjects: 206
Study 25253883 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT062070 (Cerdulatinib)
Number of subjects: 0
Study 25254044 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT (30 mg of cocoa polyphenols, 80 mg of soy isoflavones, and 2 gr of myo-inositol)
Number of subjects: 60
Study 25254044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25254070 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT + TAU
Number of subjects: 49
Study 25254070 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 49
Study 25254563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal catumaxomab (10, 20, 50, and 150 μg within 10 days)
Number of subjects: 32
Study 25254563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal catumaxomab
Number of subjects: 32
Study 25256179 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Intraplaque Hemorrhage (IPH)
Number of subjects: 113
Study 25256179 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin/Ruptured Fibrous Cap (FC)
Number of subjects: 113
Study 25256186 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography performed immediately after ICU admission
Number of subjects: 0
Study 25256545 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP) above the upper limit of autoregulation (ULA) during CPB
Number of subjects: 491
Study 25256545 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation for >48 h
Number of subjects: 491
Study 25256545 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antidepressant use
Number of subjects: 491
Study 25256545 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior stroke
Number of subjects: 491
Study 25256545 — intervention group
Group type: EXPERIMENTAL
Intervention: Congestive heart failure
Number of subjects: 491
Study 25256545 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (per year of age)
Number of subjects: 491
Study 25256566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear magnetic resonance (NMR) metabolomic profiling of spent culture media from embryos
Number of subjects: 161
Study 25257635 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotus valve system
Number of subjects: 120
Study 25258026 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative growth assessment
Number of subjects: 0
Study 25258037 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 30
Study 25258037 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 30
Study 25260365 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (6 mg/day for 3 months)
Number of subjects: 13
Study 25260365 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (after 3 months of estradiol)
Number of subjects: 13
Study 25260365 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 13
Study 25260365 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose estradiol treatment
Number of subjects: 13
Study 25260365 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effectiveness of treatment
Number of subjects: 13
Study 25260842 — intervention group
Group type: EXPERIMENTAL
Intervention: tasisulam combined with 1,000 mg/m² gemcitabine HCl (days 1 and 15)
Number of subjects: 234
Study 25260842 — intervention group
Group type: EXPERIMENTAL
Intervention: tasisulam combined with 60 mg/m² docetaxel
Number of subjects: 234
Study 25260842 — intervention group
Group type: EXPERIMENTAL
Intervention: tasisulam combined with 200 mg/m²/day temozolomide
Number of subjects: 234
Study 25260842 — intervention group
Group type: EXPERIMENTAL
Intervention: tasisulam combined with 75 mg/m² cisplatin
Number of subjects: 234
Study 25260842 — intervention group
Group type: EXPERIMENTAL
Intervention: tasisulam combined with 150 mg/day erlotinib
Number of subjects: 234
Study 25261096 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-dexamethasone
Number of subjects: 109
Study 25261096 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib
Number of subjects: 109
Study 25261424 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily with rifampicin thrice weekly
Number of subjects: 16
Study 25261424 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 800 mg twice daily with rifampicin thrice weekly
Number of subjects: 16
Study 25261424 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir alone (no rifampicin)
Number of subjects: 16
Study 25261716 — intervention group
Group type: EXPERIMENTAL
Intervention: Homemade bilayer adhesive patch (AOS)
Number of subjects: 84
Study 25261839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin (400 mg) treatment for up to 48 weeks before liver transplantation
Number of subjects: 61
Study 25262042 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 97
Study 25262042 — intervention group
Group type: EXPERIMENTAL
Intervention: PST plus antidepressant medications
Number of subjects: 97
Study 25262042 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medications alone
Number of subjects: 97
Study 25262042 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall depression treatment
Number of subjects: 97
Study 25262042 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Checklist-20
Number of subjects: 97
Study 25262042 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire-9
Number of subjects: 97
Study 25262042 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measures (SF-12, Minnesota Living with Heart Failure questionnaire, Sheehan Disability Scale)
Number of subjects: 97
Study 25262126 — intervention group
Group type: EXPERIMENTAL
Intervention: Side branch predilatation
Number of subjects: 837
Study 25262404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericoronitis pain symptoms
Number of subjects: 113
Study 25264305 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib at the standard oral dose of 250 mg twice daily
Number of subjects: 50
Study 25264305 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 50
Study 25264814 — intervention group
Group type: EXPERIMENTAL
Intervention: GFAP-BDP levels measured within 24 hours using sandwich enzyme-linked immunosorbent assay
Number of subjects: 215
Study 25264814 — intervention group
Group type: COMPARATOR
Intervention: Clinical screening alone
Number of subjects: 215
Study 25264868 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sclerosis patients (MS)
Number of subjects: 34
Study 25264868 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 34
Study 25264981 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment (10 mg/Kg/day)
Number of subjects: 40
Study 25264981 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-training on treadmill
Number of subjects: 40
Study 25264981 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and simultaneous exercise training
Number of subjects: 40
Study 25264981 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 25265186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemrix vaccine (2009-10)
Number of subjects: 3518
Study 25265186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemrix vaccine (2010-11)
Number of subjects: 3518
Study 25265186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemrix or trivalent influenza vaccine (2010-11)
Number of subjects: 3518
Study 25265315 — intervention group
Group type: COMPARATOR
Intervention: Ginseng
Number of subjects: 770
Study 25267381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for 6 months
Number of subjects: 24
Study 25267562 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (silicone metacarpophalangeal arthroplasty - SMPA)
Number of subjects: 169
Study 25267562 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 169
Study 25267741 — intervention group
Group type: EXPERIMENTAL
Intervention: Glembatumumab vedotin (1.88 mg/kg every 3 weeks)
Number of subjects: 117
Study 25267741 — intervention group
Group type: EXPERIMENTAL
Intervention: Glembatumumab vedotin (1.5 mg/kg dosing during 2 of 3 weeks)
Number of subjects: 117
Study 25267741 — intervention group
Group type: EXPERIMENTAL
Intervention: Glembatumumab vedotin (1.0 mg/kg weekly)
Number of subjects: 117
Study 25267741 — intervention group
Group type: EXPERIMENTAL
Intervention: Glembatumumab vedotin
Number of subjects: 117
Study 25267759 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplantation cyclophosphamide (PTCy) at 50 mg/kg/day on post-transplantation days +3 and +4
Number of subjects: 92
Study 25267796 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic severe hypoglycemia (HA)
Number of subjects: 503
Study 25267796 — intervention group
Group type: COMPARATOR
Intervention: No hypoglycemia (Control)
Number of subjects: 503
Study 25267955 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin (FC) levels > 30 µg/g
Number of subjects: 48
Study 25267955 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined test using FC > 30µg/g and SIBDQ score < 6
Number of subjects: 48
Study 25267955 — intervention group
Group type: EXPERIMENTAL
Intervention: SIBDQ score
Number of subjects: 48
Study 25267955 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum C-reactive protein (CRP)
Number of subjects: 48
Study 25268234 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation (MV)
Number of subjects: 1
Study 25268234 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Breathing (SB)
Number of subjects: 1
Study 25268768 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 0
Study 25268986 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery stenting
Number of subjects: 34
Study 25269577 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited-compression ultrasound (LC US)
Number of subjects: 227
Study 25269577 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporating LC US into the diagnostic approach
Number of subjects: 227
Study 25270430 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (5 g/day: 1.9-2.2 g EPA; 1.1 g DHA)
Number of subjects: 210
Study 25270430 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 210
Study 25270899 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group (eye screening at 1-2 and 3-4 months)
Number of subjects: 11541
Study 25270899 — intervention group
Group type: COMPARATOR
Intervention: Unscreened group (no eye screening at 6-9 months unless conspicuous or positive family history)
Number of subjects: 11541
Study 25270908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (n = 121)
Number of subjects: 323
Study 25270908 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (HSCT, n = 17)
Number of subjects: 323
Study 25270908 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT (n = 93)
Number of subjects: 323
Study 25271445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ketamine infusions (0.5 mg/kg over 40 minutes)
Number of subjects: 97
Study 25271871 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) treatment
Number of subjects: 257
Study 25271871 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) reintroduction
Number of subjects: 257
Study 25271941 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy bars containing isoflavones, duration: 1 week
Number of subjects: 17
Study 25271941 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy bars containing isoflavones
Number of subjects: 17
Study 25272081 — intervention group
Group type: EXPERIMENTAL
Intervention: Oka-RIT (Varilrix™) vaccine, 2 doses at 4.5 and 6.5 months post transplantation
Number of subjects: 45
Study 25272081 — intervention group
Group type: EXPERIMENTAL
Intervention: Oka-RIT (Varilrix™) vaccine
Number of subjects: 45
Study 25273116 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2-mg once-daily for 12 weeks
Number of subjects: 1596
Study 25273116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1596
Study 25273351 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prevention implantable cardioverter defibrillators (ICDs)
Number of subjects: 1189
Study 25273351 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher interleukin-6 levels
Number of subjects: 1189
Study 25273351 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein, interleukin-6, tumor necrosis factor-α receptor II, pro-BNP, cardiac troponin T
Number of subjects: 1189
Study 25273351 — intervention group
Group type: EXPERIMENTAL
Intervention: A score combining 5 biomarkers (C-reactive protein, interleukin-6, tumor necrosis factor-α receptor II, pro-BNP, cardiac troponin T)
Number of subjects: 1189
Study 25273854 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted tailored implementation strategy for delirium management
Number of subjects: 924
Study 25274049 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 week structured responsive exercise training programme (SRETP) on a training bike (three sessions per week)
Number of subjects: 39
Study 25274049 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 39
Study 25274049 — intervention group
Group type: COMPARATOR
Intervention: NACRT (neoadjuvant chemoradiotherapy)
Number of subjects: 39
Study 25274394 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation Pressure (AP)
Number of subjects: 676
Study 25274394 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate-Adjusted Augmentation Index (AI75)
Number of subjects: 676
Study 25274394 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous Cardiovascular Disease (CVD)
Number of subjects: 676
Study 25274394 — intervention group
Group type: COMPARATOR
Intervention: Autonomic Dysfunction
Number of subjects: 676
Study 25274394 — intervention group
Group type: COMPARATOR
Intervention: Retinopathy
Number of subjects: 676
Study 25276415 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (4 µg/kg)
Number of subjects: 40
Study 25276415 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 40
Study 25276665 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir (Prezista(®)) with low-dose ritonavir (DRV/r) 600/100 mg twice daily
Number of subjects: 78
Study 25277389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25277389 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study 25277389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Number of subjects: 0
Study 25278335 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise program (16 weeks, 3 times per week at 50% to >70% oxygen uptake reserve)
Number of subjects: 18
Study 25278335 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise program
Number of subjects: 18
Study 25279138 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized neuropsychological test battery
Number of subjects: 26
Study 25279222 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin at 14 mg/m² as a 4-hour intravenous infusion on days 1, 8, and 15 of 28-day cycles for up to 6 cycles
Number of subjects: 100
Study 25279222 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin treatment
Number of subjects: 100
Study 25279930 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 30
Study 25279930 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort Score (CS)
Number of subjects: 30
Study 25279930 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS 70.5
Number of subjects: 30
Study 25279930 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS ≤60
Number of subjects: 30
Study 25279930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation/analgesia using remifentanil and propofol
Number of subjects: 30
Study 25280062 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) enoxaparin at a standard dose of 1 mg/kg every 12 h
Number of subjects: 10
Study 25280062 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 10
Study 25280062 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with malignancy and VTE
Number of subjects: 10
Study 25280062 — intervention group
Group type: COMPARATOR
Intervention: Cancer-free, age-matched, normal controls
Number of subjects: 10
Study 25280575 — intervention group
Group type: EXPERIMENTAL
Intervention: Age over 75 years
Number of subjects: 176
Study 25280575 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval between symptom onset and diagnosis below 7 months
Number of subjects: 176
Study 25280575 — intervention group
Group type: EXPERIMENTAL
Intervention: Decline of body weight before diagnosis exceeding 2 BMI units
Number of subjects: 176
Study 25280575 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Rating Score below 31 points
Number of subjects: 176
Study 25280575 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall one-year mortality rate
Number of subjects: 176
Study 25280913 — intervention group
Group type: EXPERIMENTAL
Intervention: Graph theoretical analysis of network parameters
Number of subjects: 120
Study 25280913 — intervention group
Group type: EXPERIMENTAL
Intervention: Graph theoretical analysis
Number of subjects: 120
Study 25280960 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adiposity index (VAI)
Number of subjects: 464
Study 25280960 — intervention group
Group type: COMPARATOR
Intervention: Waist circumference (WC)
Number of subjects: 464
Study 25280960 — intervention group
Group type: COMPARATOR
Intervention: Waist-to-height ratio (WHtR)
Number of subjects: 464